Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Stock data | 2024 | Change |
---|---|---|
Price | $1.08 | N/A |
Market Cap | $1.32M | N/A |
Shares Outstanding | 1.22M | N/A |
Employees | 16.00 | N/A |